Barclays Maintains Overweight on Progyny, Lowers Price Target to $23
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Glen Santangelo maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $29 to $23.
Barclays analyst Glen Santangelo maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $29 to $23.